Boylston Surgical LLC

Boylston Surgical LLC, founded in 2024, develops orthobiologic products for soft tissue repair and regenerative medicine. The company's flagship product, BioTend, is a woven poly-L-lactic acid mesh designed for tendon and ligament surgical repairs. BioTend has FDA clearance for use in major tendon and ligament repair procedures. The product's woven design mimics the mechanical properties of human tendons and ligaments, providing stronger, more functional repairs. The poly-L-lactic acid fibers safely absorb into the body over 9–12 months, eliminating the need for removal surgery. After over 3,000 surgical procedures, BioTend has demonstrated no adverse safety events or patient complications. The company builds on 10 years of foundational research and development conducted by Synthasome, its predecessor organization. Boylston Surgical's mission focuses on advancing regenerative medicine through high-quality scientific and engineering research to repair, regenerate, or replace damaged soft tissues including tendons, ligaments, and articular cartilage. The company serves orthopedic surgeons and surgical centers performing soft tissue repair procedures.